Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tumor Cell Vaccine and GM-CSF in Multiple Myeloma After Second Stem Cell Transplant
NCT00019097Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 1995
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Autologous FL vaccine in multiple myeloma (MM) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Cellular and humoral immunity against the unique idiotype expressed on the surface of myeloma cells, Clinical efficacy of the regimen and 1 more. Started Jul 1995; status: completed.
02
Drugs
Autologous FL vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00019097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019097.